Lonza Group Ltd (Lonza) manufactures and supplies biotech and chemical ingredients to the pharmaceutical, healthcare, and life science industries. The company specializes in mammalian and microbial biologics, bioconjugates, mRNA, and drug product services, among other areas. Additionally, it offers contract development and manufacturing services for small molecules, with an emphasis on drug substance, drug product, and particle engineering. The company collaborates with a wide range of customers, from emerging biotechs to global pharmaceutical companies, to transform therapeutic discoveries into treatments. The company offers integrated solutions across all platforms and modalities, providing end-to-end CDMO services. Lonza supports over 660 pre-clinical and clinical large molecules and more than 65 commercial large molecules. The company also provides specialized services in cell and gene therapies, mRNA/LNP products, and microbial fermentation.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lonza continually invests in R&D to anticipate future demand while meeting current market needs for diverse and complex ADCs. The company's position in bioconjugation innovation was strengthened by integrating Synaffix and its GlycoConnect platform. Lonza accelerates the development of bioconjugates by combining technology access, discovery services, and manufacturing capabilities. The company collaborates with leading technology providers to offer a variety of conjugation technologies, linkers, and payloads to drug developers. Lonza offers a robust, integrated, and end-to-end bioconjugates offering across biologics, payload-linkers, bioconjugation, and drug products. The company is involved in the development of dual-payload ADCs and antibody-oligonucleotide conjugates (AOCs), addressing technical challenges to enable successful development and commercialization. Lonza is also advancing in vivo CAR-T cell therapies and supporting needle-free GLP-1 delivery through innovative platforms and technologies. The R&D unit of Lonza is responsible for managing the company's R&D activities, including the development of bioconjugates, dual-payload ADCs, AOCs, in vivo CAR-T cell therapies, and needle-free GLP-1 delivery platforms. In FY2025, the company spent CHF112 million on its R&D activities, which as a percentage of revenue stood at 1.7%. As of December 2025, the company had 2,804 trademark filings and 1,110 small and large molecules, along with 306 brands. Lonza has 420 active patent families.